Who Director-General Dr tedros adhanom Ghebreyesus, said that the results of clinical trials in the UK steroid dexamethasone for the treatment of COVID-19 became a scientific breakthrough.
He stressed that it is the first drug that reduced mortality among patients with COVID-19 who need oxygen therapy or mechanical ventilation, according to “RIA Novosti”.
Chapter who is also called the test results “great news.”
Held in Oxford study showed that the anti-inflammatory drug dexamethasone reduces the risk of death in patients with COVID-19, connected to devices of artificial ventilation of lungs (IVL), 35% among patients receiving oxygen at 20%. British authorities on Tuesday, June 16, approved dexamethasone for the treatment of COVID-19.
Earlier, on 15 June, it was reported that the office for quality control of food and medicine under the Ministry of health and social services withdrew emergency resolution for supply to hospitals antimalarial drugs hydroxychloroquine and chloroquine for the treatment of patients with coronavirus infection.
SEE ALSO
—
